Exactech plans to incorporate XpandOrtho’s technology to enhance its ExactechGPS computer-assisted surgery system, the only navigation system that supports both shoulder and knee replacement
Exactech develops and markets orthopaedic implant devices, related surgical instruments, biologic materials and computer-assisted surgery technologies to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated because of injury or diseases such as arthritis.
XpandOrtho is a privately held medical device and technology company that is committed to improving the standard of care in total knee replacement surgeries by providing measurable and consistent results to all surgeons and patients.
Managing a patient’s soft tissue is an important aspect of knee replacement surgery. XpandOrtho received clearance from the U.S. Food and Drug Administration for an electronic, soft tissue-balancing instrument for total knee arthroplasty. The intra-articular device uses multiple sensors within the knee joint to guide soft tissue balancing. The device uses a novel pneumatic-based bellows system, which wirelessly communicates with a display to provide the surgeon gap balancing feedback throughout the knee’s range of motion.
Exactech CEO David Petty stated, “The acquisition of XpandOrtho supports Exactech’s growth strategy and commitment to improving surgeon experience and patient outcomes. Their innovative ligament balancing technology provides a strong framework for integration into our ExactechGPS system to further advance our award-winning Truliant® Total Knee System. We look forward to collaborating with XpandOrtho founders Cliff Colwell and Darryl D’Lima on continued development of advanced knee replacement technology.”
Darryl D’Lima M.D., Ph.D., and Clifford W. Colwell, Jr., M.D., report that they feel “privileged to have been purchased by an outstanding orthopaedic device company such as Exactech. This allows our technology, which has been in development for more than seven years, to be brought to market for the benefit of surgeons and their patients.”